NanoViricides, Inc. (NYSE American: NNVC) announced that its antiviral drug candidate NV-387 may address the growing global measles outbreak, citing recent case surges including more than 18,000 suspected infections in Bangladesh and rising cases in the United States. The company stated that NV-387 has demonstrated safety in Phase I clinical trials and efficacy in animal models, positioning it as a potential therapeutic complement to vaccination by reducing transmission and treating infected patients, particularly among vulnerable populations, while also noting plans to pursue orphan and rare pediatric disease designations with the FDA.
NV-387 is a broad-spectrum antiviral drug that the company plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. According to the company, NV-387 has shown effectiveness in animal models for Monkeypox (MPox), Smallpox, and Measles. The successful completion of a Phase I human clinical trial in healthy volunteers with no reported adverse events supports its safety profile, and NanoViricides is now focused on advancing NV-387 into Phase II human clinical trials.
The announcement comes as measles cases continue to rise globally, with significant outbreaks in regions with low vaccination coverage. The potential for NV-387 to serve as a therapeutic option could help mitigate the impact of the virus, especially in immunocompromised individuals or those unable to receive vaccines. The company's pursuit of orphan and rare pediatric disease designations underscores the unmet medical need in treating measles, which can lead to severe complications and death.
For more details, the full press release is available at https://ibn.fm/YQsvK. Additional updates on NanoViricides can be found in the company's newsroom at https://ibn.fm/NNVC.
